Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Deliv ; 24(1): 92-98, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28155569

ABSTRACT

PURPOSE: To compare the demethylvancomycin's diffusion-deposition characteristics in the ocular solid tissues of sustained subtenon drug delivery with subconjunctival injection. METHOD: Sixty adult white rabbits were randomly assigned to the subtenon drug delivery group and the subconjunctival injection group. The subtenon drug delivery group was continuously infused demethylvancomycin to the subtenon of rabbits. The subconjunctival injection group was injected demethylvancomycin to the subconjunctival of rabbits. Cornea, iris and sclera were collected for high-performance liquid chromatography analyses to determine drug concentrations at one hour, three hours, six hours, 12 h and 24 h of drug administration. WinNonlin 6.3 was used to calculate the parameters of cumulative area under the curve (AUCcum) of demethylvancomycin. RESULTS: The peak levels of demethylvancomycin concentration of the subtenon drug delivery group and the subconjunctival injection group were 92.406 ± 21.555 and 51.778 ± 14.001 µg/g in cornea, 28.451 ± 10.229 µg/g and 42.271 ± 27.291 µg/g in iris, 153.166 ± 51.738 µg/g and 57.423 ± 18.480 µg/g in sclera. The differences of concentrations between the two groups in cornea and sclera were statistically significant (F = 487.775, p < 0.001; F = 132.748, p < 0.001). The difference in iris was not statistically significant (F = 4.848, p = 0.064). The maximum of AUCcum of the subtenon drug delivery group and the subconjunctival injection group was 1808.23 h * µg/g and 273.73 h * µg/g in cornea, 489.12 h * µg/g and 216.16 h * µg/g in iris and 2166.34 h * µg/g and 392.57 h * µg/g in sclera at 24 h of drug administration. CONCLUSION: The sustained subtenon drug delivery had a better drug permeability and accumulation in the intraocular solid tissue compared to subconjunctival injection, which demonstrated it was probably a promising and effective approach for treating posterior segment diseases and endophthalmitis.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Vancomycin/analogs & derivatives , Vancomycin/administration & dosage , Animals , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacokinetics , Area Under Curve , Biological Availability , Chromatography, High Pressure Liquid , Cornea/metabolism , Delayed-Action Preparations , Diffusion , Drug Compounding , Infusions, Parenteral , Injections, Intraocular , Iris/metabolism , Permeability , Rabbits , Sclera/metabolism , Technology, Pharmaceutical/methods , Tissue Distribution , Vancomycin/chemistry , Vancomycin/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...